Aileron Therapeutics, Inc. (ALRN) News Headlines

▮ More

Date

Headline

7/1/2021 8:12:22 AM Aileron Therapeutics Begins Phase 1b Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer

1/11/2021 6:03:00 AM Pre-market Movers In Healthcare Sector: TRXC, JAGX, ALRN, BNGO, MBRX, APDN…

1/6/2021 9:53:24 AM Aileron Announces $35.9 Mln Registered Direct Offering; Stock Down

1/5/2021 6:01:14 AM Pre-market Movers In Healthcare Sector: CHEK, SYN, NSPR, ZOM, BNGO, VRAY...

12/21/2020 8:12:10 AM Aileron Therapeutics Provides Business Update And Outlines Strategic Priorities For 2021

10/26/2020 6:53:45 AM Pre-market Movers In Healthcare Sector: ALRN, SELB, CODX, IPHA, NNOX…

8/11/2020 1:57:59 AM CPRX Plunges As MuSK-MG Trial Flops, MESO Awaits FDA Panel Review, EQ Soars After-hrs

8/4/2020 3:31:42 AM ALRN To Report Data In Q4, IMUC Hits New High, VYGR Pulls Out Of ABBV Deal, VNDA To Face FDA In Dec.

6/1/2020 7:20:26 AM Aileron Therapeutics Reports Positive Interim Data From Phase 1b/2 Clinical Trial Of ALRN-6924

4/3/2018 2:28:41 PM Jefferies Is Increasing Aileron Therapeutics, Inc. (ALRN) FY19 Estimate To -2.26 From -3.01

4/3/2018 2:28:24 PM Jefferies Is Increasing Aileron Therapeutics, Inc. (ALRN) FY18 Estimate To -2.24 From -2.36

11/9/2017 8:26:47 PM Jefferies Is Lowering Aileron Therapeutics, Inc. (ALRN) FY19 Estimate To -3.01 From -2.65

11/9/2017 8:26:13 PM Jefferies Is Lowering Aileron Therapeutics, Inc. (ALRN) FY18 Estimate To -2.36 From -2.05

7/24/2017 7:16:18 AM Jefferies Starts Aileron Therapeutics, Inc. (ALRN) At Buy With $20 Price Target

Older Articles